Loading...
CMRA logo

Comera Life Sciences Holdings, Inc.OTCPK:CMRA Stock Report

Market Cap US$3.1k
Share Price
n/a
1Y-50.0%
7D0%
1D9,900.0%
Portfolio Value
​
View

Comera Life Sciences Holdings, Inc.

OTCPK:CMRA Stock Report

Market Cap: US$3.1k

Comera Life Sciences Holdings (CMRA) Stock Overview

A preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. More details

CMRA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($3K)

Latest financial reports are more than a year old

Shares are highly illiquid


CMRA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW499,625 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
499,625 investors already sharing narratives
View all narratives

Comera Life Sciences Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Comera Life Sciences Holdings
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$0.0002
52 Week LowUS$0.000001
Beta0
1 Month Change9,900.00%
3 Month Changen/a
1 Year Change-50.00%
3 Year Change-99.90%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Oct 18

Comera Life Sciences rises on positive preclinical data from Sequrus study

Comera Life Sciences (NASDAQ:CMRA) is trading 6.1% higher after it announced positive data from Sequrus study. The company said preclinical data showed that its caffeine-based SQore excipient did not result in local or systemic toxicity and had no impact on any measured pharmacokinetic parameters of ipilimumab when administered under the skin. Comera is using its formulation platform SQore to enable subcutaneous (SQ) delivery of IV drugs such as monoclonal antibodies. "Based on our four preclinical studies completed to date with our lead excipient, we believe that our technology has the potential to bring the freedom of self-administration to existing life-changing therapies," the company said. The results also showed that caffeine had no impact on ipilimumab (branded as Yervoy to treat skin cancer) half-life and no effect on pharmacokinetic data for both the IV and SQ groups.
Seeking Alpha • Oct 04

Comera life sciences expands woburn operations

Comera Life Sciences Holdings (NASDAQ:CMRA) has announced the expansion of its Woburn, Mass operations. The space at 12 Gill St. in Woburn, Mass., spans over 5,000 square feet and includes an expanded laboratory space for R&D activities as well as new executive offices. Comera Life Sciences Holdings is a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. The Comera team was joined by state and local officials and members of the biotech industry, including Massachusetts State Senator Cindy F. Friedman, Massachusetts State Representative Richard M. Haggerty, Woburn Mayor Scott Galvin and Massachusetts Biotechnology Council (MassBio) President and COO Kendalle Burlin O’Connell. The expansion of our headquarters in Woburn is a milestone achievement as we continue to advance our internal pipeline and collaborations with some of the largest biopharmaceutical companies,” said Jeffrey Hackman, Chairman and CEO of Comera. Comera is developing a portfolio of proprietary injectable therapeutics – called subcutaneous (SQ) therapeutics – with the goal of making it possible for patients to administer medications that historically have been administered only by intravenous (IV) infusion. Access to necessary and lifesaving medications is a huge barrier for many in our commonwealth said Friedman, Senate Chair of the Joint Committee on Health Care Financing. The work of Comera Life Sciences seeks to directly address this barrier by providing a more convenient and equitable way to access these medications. Source: Press Release
Seeking Alpha • Aug 31

Comera Life Sciences announces up to $15M purchase agreement with Arena

Comera Life Sciences (NASDAQ:CMRA) said on Wednesday that it had entered into a purchase agreement with Arena Business Solutions Global for up to $15M of the company’s common stock, with an option to increase by an additional $15M to $30M. "The line of credit provides the opportunity to invest in our pipeline and proprietary formulation platform, SQore, which is designed to transform intravenous biologics into subcutaneous versions that patients can self-administer in a single dose,” said Jeffrey Hackman, Chief Executive Officer of Comera. Comera will have the right and the sole discretion to sell to Arena up to $15M worth of shares over a 36-month period subject to certain limitations. Comera will control the timing and amount of any future investment and Arena will be obligated to make purchases in accordance with the purchase agreement and at a price based on 96% of the volume-weighted average trading price of common stock on the day of each sale.
Seeking Alpha • Aug 10

Comera Life Sciences GAAP EPS of -$1.14, revenue of $0.15M

Comera Life Sciences press release (NASDAQ:CMRA): Q2 GAAP EPS of -$1.14. Revenue of $0.15M (+114.3% Y/Y). Comera had $5.0 million in cash, cash equivalents and restricted cash as of June 30, 2022. Shares -1.4% AH.
Analysis Article • May 27

Comera Life Sciences Holdings (NASDAQ:CMRA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

CMRAUS BiotechsUS Market
7D0%2.3%0.8%
1Y-50.0%42.3%20.2%

Return vs Industry: CMRA underperformed the US Biotechs industry which returned 41.1% over the past year.

Return vs Market: CMRA underperformed the US Market which returned 18.6% over the past year.

Price Volatility

Is CMRA's price volatile compared to industry and market?
CMRA volatility
CMRA Average Weekly Movementn/a
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: CMRA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine CMRA's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aMichael Campbellcomeralifesciences.com

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Comera Life Sciences Holdings, Inc. Fundamentals Summary

How do Comera Life Sciences Holdings's earnings and revenue compare to its market cap?
CMRA fundamental statistics
Market capUS$3.07k
Earnings (TTM)-US$9.35m
Revenue (TTM)US$1.00m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is CMRA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMRA income statement (TTM)
RevenueUS$1.00m
Cost of RevenueUS$264.88k
Gross ProfitUS$735.52k
Other ExpensesUS$10.09m
Earnings-US$9.35m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did CMRA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 10:01
End of Day Share Price 2026/06/08 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Comera Life Sciences Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.